

Immunovative, Inc.
Form 10-Q/A
November 26, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q/A
(Amendment No. 2)

b QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 000-53723

IMMUNOVATIVE, INC.
(f/k/a Novo Energies Corporation)
(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of Identification No.)

65-1102237
(I.R.S. Employer or organization)

39 Old Ridgebury Road
Danbury, CT 06180
(Address of principal executive offices) (Zip Code)

(917) 796-9926
(Registrant's telephone number, including area code)

Securities registered under Section 12(b) of the Exchange Act:
None

Securities registered under Section 12(g) of the Exchange Act:
Common Stock, \$.00001 Par Value

(Title of class)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during

Edgar Filing: Immunovative, Inc. - Form 10-Q/A

the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer Accelerated Filer Non-Accelerated Filer Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 1, 2012 the registrant had 186,416,669 shares of its Common Stock, \$0.00001 par value, outstanding.

Explanatory Note

The purpose of this Amendment No. 2 to Immunovative, Inc. Quarterly Report on Form 10-Q and Form 10-Q/A, Amendment No. 1, for the quarterly period ended September 30, 2012, filed with the Securities and Exchange Commission on November 16, 2012 (the "Form 10-Q") and November 19, 2012 (the "Form 10-Q/A"), respectively, is solely to correct the cover page in regards to the line "Indicate by check mark whether the registrant is a shell company (as definable in Rule 12b-2 of the Exchange Act)." The prior submission was missing the empty box next to the "Yes" therefore the checked box was uncertain as to the answer. The box is checked as "No" as has previously been submitted.

No other changes have been made to the Form 10-Q or Form 10-Q/A. This Amendment No. 2 to the Form 10-Q and Form 10-Q/A, speaks as of the original filing date of the Form 10-Q and Form 10-Q/A, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q and Form 10-Q/A.

ITEM 6. EXHIBITS.

Exhibit Certification of Chief Executive Officer
31.1

Exhibit Certification of Chief Financial Officer
31.2

Exhibit Certification of Chief Executive Officer
32.1

Exhibit Certification of Chief Financial Officer
32.2

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

IMMUNOVATIVE, INC.
(formerly Novo Energies Corporation)
(Registrant)

Date: November 26, 2012

/s/ Seth Shaw
Seth Shaw
Chief Executive Officer

Date: November 26, 2012

/s/ Bruce Harmon
Bruce Harmon
Chief Financial Officer